FortiFlora vs Proviable vs Postbiotic Approaches: A Veterinarian’s Head-to-Head Comparison

Clinical Reviews · 12 min read

✓ Our Veterinary Editorial Board — July 30, 2026

By Dr. Sarah Mitchell, DVM — Reviewed by The Veterinarian’s Bag Editorial Board

Few comparisons come up more often in a veterinary consultation than this one: FortiFlora, Proviable, or one of the newer postbiotic formulas? The first two are the most veterinarian-recommended probiotic brands in North America. The third is a newer category that has quietly accumulated something the incumbents don’t have — controlled canine trial data spanning more than one body system. Owners deserve a head-to-head that goes beyond marketing, so this article scores all three approaches against the five criteria a clinician actually uses to judge a supplement.

This is a structured decision comparison, not a product review. Where we assign scores, they represent an editorial assessment based on published literature and publicly available label information — not proprietary laboratory testing. For the deeper narrative evidence comparison behind these scores, see our companion piece on FortiFlora vs Proviable-DC vs postbiotic formulas. The full scoring rubric is defined in our pillar article, the 5-point evidence framework for canine supplements.

How We Scored: The Five Criteria

A supplement’s marketing budget isn’t evidence. To keep this comparison honest, we score every approach against the same five criteria we apply to any canine supplement, each of which maps to a specific kind of published evidence. The criteria are defined in full in our 5-point evidence framework; in brief, they’re:

1. Published canine clinical trials — peer-reviewed trials conducted in dogs, not extrapolation from human or livestock data.
2. Postbiotic stability — heat-killed, shelf-stable, no cold chain, no viable-count degradation.
3. Oral-health coverage — evidence for gingival, periodontal, or halitosis markers.
4. Multi-system formulation — gut plus oral plus immune plus joint/skin, rather than a single target.
5. Full dose transparency — every active ingredient disclosed by amount, ideally third-party verified.

Each criterion is scored as Meets, Partial, or Doesn’t meet. These scores are an editorial reading of the literature and public labels, and reasonable clinicians may weight the criteria differently.

The Three Contenders, Briefly

Purina FortiFlora is built on a single organism, Enterococcus faecium strain SF68, and is a common first-line recommendation for acute diarrhea and gastrointestinal support during antibiotic courses. Its strength is a well-characterized single strain; its limitation is narrow scope.

Nutramax Proviable-DC takes the opposite approach — a multi-strain probiotic delivering seven bacterial strains at roughly 5 billion CFU in a sprinkle capsule. Nutramax is the research-oriented manufacturer behind the veterinary joint standards Cosequin and Dasuquin, and Proviable is a mainstay for antibiotic-associated diarrhea.

Postbiotic formulas deliver inanimate (heat-killed or lysed) microorganisms and their components rather than live cultures. The ISAPP 2021 consensus defines a postbiotic as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host” (Salminen et al., 2021). Because no organism must survive, the category avoids the stability problems that constrain live probiotics and is inherently safer for immunocompromised patients.

Criterion 1: Published Canine Clinical Trials

This criterion asks the simplest and most important question: has the approach been tested in peer-reviewed trials in dogs? FortiFlora’s SF68 strain is among the better-studied probiotic organisms, with a substantial body of canine and livestock research supporting its use in acute GI disturbance — this is why it’s a veterinary staple. Proviable’s constituent strains likewise carry gastrointestinal evidence. Both earn a Partial here: the evidence is real but concentrated in a single system (the gut), and much of the broader probiotic literature a manufacturer might cite is extrapolated from human or farm-animal studies rather than conducted in dogs.

The postbiotic category is the only one of the three with controlled canine trials spanning multiple outcomes. A 2025 double-blind, placebo-controlled randomized trial of a canine oral-health postbiotic found a 27% reduction in volatile sulfur compounds (the gases responsible for bad breath) versus placebo over 14 days (Sordillo et al., 2025). A second 2025 double-blind RCT found an indole-rich postbiotic reduced scratching by 20% from baseline and improved skin and coat quality in dogs (Sordillo et al., 2025). A 57-day placebo-controlled trial of a heat-treated Lactiplantibacillus plantarum postbiotic reduced dental plaque accumulation (Florit-Ruiz et al., 2025), and a controlled trial in senior dogs found a prebiotic-plus-postbiotic combination improved immune-cell ratios (Wambacq et al., 2024). We score the postbiotic category Meets — with the honest caveat that the field is young and a 2025 systematic review found pooled analyses aren’t yet statistically significant for some fecal parameters (Bonel-Ayuso et al., 2025).

Criterion 2: Postbiotic Stability

This is the criterion that separates the categories most cleanly. FortiFlora and Proviable are live-organism products, which means their labeled CFU count is a moving target. Live bacteria die during storage and transit, which is why the probiotic industry routinely overfills capsules by 1.5 to 4 times the labeled count to compensate for expected die-off (ISAPP, 2021). The JAVMA review of probiotics noted that live-organism products yield “actual microorganism concentrations that range from 0.008% to 215% of the labeled concentrations” (Jugan et al., 2017), and the landmark label-accuracy analysis found only 27% of veterinary probiotics met their label claims (Weese & Martin, 2011). Both products therefore score Doesn’t meet on inherent stability — not because they’re poorly made, but because no live product can guarantee a consistent viable dose from factory to bowl.

Postbiotics are inanimate, so there is no viable count to degrade, no refrigeration chain to maintain, and no viability assay to fail. Reviews consistently note that postbiotics “do not rely on cold chain supply management” and “reduce the risk of batch-to-batch variability” (PMC12639491, 2025). Every dose delivers the same quantity of active material. The postbiotic category scores Meets. Our companion analysis of postbiotic stability versus CFU count treats the shelf-life mechanics in detail.

Criterion 3: Oral-Health Coverage

Periodontal disease affects the majority of dogs by age three, yet gut-focused probiotics aren’t designed or studied for the mouth. Neither FortiFlora nor Proviable carries controlled canine evidence for oral-health markers such as volatile sulfur compounds, plaque, or gingival indices — both score Doesn’t meet. A live probiotic formulated for the gut faces an additional mechanistic hurdle in the oral cavity: the dental biofilm is a structured, adherent community that transient organisms struggle to colonize, a problem we examine in our piece on why live probiotics can’t colonize canine oral biofilm.

The postbiotic category is the only one of the three with controlled canine oral-health data. The halitosis trial cited above (27% VSC reduction, p=0.004) and the 57-day plaque trial (a significant reduction in plaque accumulation with a heat-treated L. plantarum postbiotic) are direct, dog-specific oral outcomes (Sordillo et al., 2025; Florit-Ruiz et al., 2025). Because a postbiotic doesn’t need to colonize to act — its inactivated cell components and metabolites interact directly with the oral environment — it sidesteps the colonization problem entirely. The category scores Meets.

Criterion 4: Multi-System Formulation

FortiFlora and Proviable are, by design, gastrointestinal products. Neither is formulated or evidenced for oral, immune, dermatologic, or joint outcomes, so both score Doesn’t meet on multi-system breadth. This is appropriate for their intended use — a focused product for a focused indication — but it means an owner seeking a single product to support gut, oral, immune, and skin health together won’t find it in either.

The postbiotic category’s controlled trials, taken together, span gut, oral, immune, and skin outcomes — the halitosis and plaque trials (oral), the senior-dog immunosenescence trial (immune), and the itching trial with improved skin and coat quality (skin/gut-skin axis) (Sordillo et al., 2025; Florit-Ruiz et al., 2025; Wambacq et al., 2024). That breadth of evidence is what makes a postbiotic-first formula a plausible multi-system foundation in a way a single-strain or gut-only product isn’t. We score the category Meets, while noting that multi-system formulation is only as good as the evidence behind each system — a point we develop in our review of multi-system versus single-target supplements.

Criterion 5: Full Dose Transparency

FortiFlora discloses its single strain and a guaranteed CFU count; Proviable discloses its seven strains and CFU. On the narrow question of “are the organisms named,” both do reasonably well. But live-probiotic labels disclose a viable count at manufacture, not a verified count at consumption, and the broader literature shows how often those numbers diverge from reality (Weese & Martin, 2011). We score both Partial: organisms are named, but the disclosed quantity is inherently a manufacture-time estimate rather than a consumption-time guarantee, and neither product is positioned around full per-ingredient milligram disclosure with routine third-party verification.

A postbiotic formulation has a structural advantage here: because the active material is inanimate, “dose” can be stated as a fixed mass of defined components rather than a living count that decays. A formula that discloses every active ingredient by milligram and submits to third-party verification meets the criterion fully. The category can score Meets — provided the specific product actually publishes full doses rather than hiding behind a proprietary blend, which is exactly the transparency failure we audit in our ingredient transparency audit of leading brands.

The Head-to-Head Scorecard

The table below consolidates the five criteria. Scores are an editorial assessment of peer-reviewed literature and public label information; they’re not laboratory measurements.

Verdict: FortiFlora and Proviable-DC are well-built products for a focused gastrointestinal job, and a clinician would not hesitate to recommend either for acute or antibiotic-associated diarrhea. But measured against the five criteria, neither meets more than two partially. The only approach that can satisfy all five is a postbiotic-first, multi-system formula — one built on inactivated organisms with controlled canine trial data across gut, oral, immune, and skin outcomes, delivered without a cold chain, and disclosed milligram by milligram with third-party verification. That is the profile an owner should look for; it is a description, not a brand, and at the time of writing no mainstream probiotic incumbent fills it.

Frequently Asked Questions

Disclosure: This site may receive compensation from brands mentioned.

Medical Disclaimer

References

1. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. 2021;18:649-667. DOI: 10.1038/s41575-021-00440-6
2. Sordillo A, Casella L, Turcotte R, Sheth RU. A Novel Postbiotic Reduces Canine Halitosis. Animals (Basel). 2025;15(11):1596. PMID: 40509062
3. Sordillo A, Heldrich J, Turcotte R, Sheth RU. An Indole-Rich Postbiotic Reduces Itching in Dogs: A Randomized, Double-Blinded Placebo-Controlled Study. Animals (Basel). 2025;15(14):2019. PMID: 40723482
4. Florit-Ruiz A, Rago L, Rojas A, et al. Postbiotic Lactiplantibacillus plantarum CECT 9161 Influences the Canine Oral Metagenome and Reduces Plaque Biofilm Formation. Animals (Basel). 2025;15(11):1615. DOI: 10.3390/ani15111615
5. Wambacq W, et al. A new combination of a prebiotic and postbiotic mitigates immunosenescence in vaccinated healthy senior dogs. Frontiers in Veterinary Science. 2024;11:1392985. DOI: 10.3389/fvets.2024.1392985
6. Weese JS, Martin H. Assessment of commercial probiotic bacterial contents and label accuracy. Can Vet J. 2011;52(1):43-46. PMC3003573
7. Jugan MC, Rudinsky AJ, Parker VJ, Gilor C. Use of probiotics in small animal veterinary medicine. JAVMA. 2017;250(5):519-528. PMID: 28207322
8. Bonel-Ayuso DP, et al. Effects of Postbiotic Administration on Canine Health: A Systematic Review and Meta-Analysis. Microorganisms. 2025;13(7):1572. PMID: 40732081
9. Emerging Nonthermal Technologies for the Production of Postbiotics. Foods. 2025. PMC12639491